By focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, this ready reference provides the critical knowledge needed to develop entirely novel therapeutics and to target new viruses. It begins with a general discussion of antiviral strategies, followed by a broad survey of known viral targets, such as reverse transcriptases, proteases,neuraminidases, RNA polymerases, helicases and primases, as well as their known inhibitors. The final section contains several cases studies of recent successful antiviral drug development. Edited by Erik de Clercq, the world authority on small molecule antiviral drugs, who has developed more new antivirals than anyone else. INDICE: Outlook of the Antiviral Drug Era, now more than 50 Years after Description of the First Antiviral Drug Inhibition of HIV Entry Targeting Integration Beyond Strand Transfer. Development of Second Generation HIV Integrase Inhibitors From Saquinavir to Darunavir, the Impact of 10 Years of Medicinal Chemistry on a Lethal Disease Acyclic and Cyclic Nucleoside Phosphonates Helicase-Primase Inhibitors - A New Approach to Combat Herpes Simplex Virus and Varicella-Zoster Virus Cyclophilin Inhibitors Alkoxyalkyl Ester Prodrugs of Antiviral Nucleoside Phosphates and Phosphonates Maribavir: A Novel Benzimidazole Ribonucleoside for the Prevention and Treatment of Cytomegalovirus Diseases Anti-HCMV Compounds Lethal Mutagenesis as an Unconventional Approach to Combat HIV Recent Progess in the Development of HCV Protease Inhibitors Antiviral RNAi, How to Silence Viruses Neuraminidase Inhibitors as Anti-Influenza Agents From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Non-NucleosideReverse Transcriptase Inhibitor (NNRTI)
- ISBN: 978-3-527-32696-9
- Editorial: Wiley-VCH
- Encuadernacion: Cartoné
- Páginas: 432
- Fecha Publicación: 06/04/2011
- Nº Volúmenes: 1
- Idioma: Inglés